Elsevier

Life Sciences

Volume 56, Issues 11–12, 10 February 1995, Pages 931-938
Life Sciences

Molecular pharmacology and physiology: Structure-function relationship
Diverse pre- and post-synaptic expression of m1–m4 muscarinic receptor proteins in neurons and afferents in the rat neostriatum

https://doi.org/10.1016/0024-3205(95)00030-AGet rights and content

Abstract

We have utilized subtype specific antibodies to determine the cellular and subcellular distributions of the muscarinic acetylcholine receptor subtypes that are highly expressed in the rat striatum (m1–m4). Each receptor is expressed in distinct populations of striatal neurons in the relative proportions predicted by their mRNAs. They concentrate at post-synaptic sites and each of the four subtypes are also transported to pre-synaptic sites. m2 appears to be the only presynaptic autoreceptor in the striatum, but it is also localized in noncholinergic terminals. These distinct pre- and post-synaptic localizations suggest that muscarinic receptor subtype diversity evolved to enable increasingly complex responses to acetylcholine release.

References (28)

  • A. Levey et al.

    FEBS Lett.

    (1990)
  • M.T. Vilaró et al.

    Neuroscience

    (1991)
  • M.T. Vilaró et al.

    Neuroscience

    (1992)
  • P.N. Izzo et al.

    Neuroscience

    (1987)
  • R. Dimova et al.

    Neuroscience

    (1980)
  • P.A. Lapchak et al.

    Brain Res.

    (1989)
  • J. Bolam et al.

    Neuroscience

    (1984)
  • R. Dimova et al.

    Neuroscience

    (1993)
  • B.H. Wainer et al.

    Brain Res.

    (1984)
  • J.M. Kemp

    Brain Research

    (1968)
  • A.I. Levey et al.

    J. Neurosci.

    (1991)
  • S.M. Hersch et al.

    J. Neurosci.

    (1994)
  • N. Buckley et al.

    J. Neurosci.

    (1988)
  • V. Bernard et al.

    J. Neurosci.

    (1992)
  • Cited by (50)

    • Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease

      2019, Neurochemistry International
      Citation Excerpt :

      Several receptor localization studies in rodents report a predominant expression of M4 mAChRs within the striatum (45% of total striatal mAChRs) whereas M1 and M2 mAChRs are expressed at 30% and 20% of total striatal mAChRs, respectively (Chapman et al., 2011; Volpicelli and Levey, 2004; Waelbroeck et al., 1990; Yasuda et al., 1993). M3 mAChRs are clearly less abundant and M5 mAChRs are expressed at a very low level (Chapman et al., 2011; Hersch and Levey, 1995; Weiner et al., 1990; Yasuda et al., 1993). nAChRs constitute the second type of cholinergic receptors.

    • Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M<inf>4</inf> PAM VU0467154

      2018, Neuropharmacology
      Citation Excerpt :

      The current validation of the cognitive enhancing effects of the M4 PAM mechanism across 3 distinct cognitive assays that are in part dependent on different brain regions (Sacchetti et al., 2002; Zhang et al., 2001) after administration alone or in combination with a pharmacological challenge using both Pavlovian conditioning and operant approaches under conditions of a 10-day, once-daily dosing regimen provides further support for the clinical development of M4 PAMs to address one or more cognitive impairments observed in individuals with schizophrenia. Interestingly, M4 mAChRs are expressed throughout limbic and cortical brain regions known to be disrupted in individuals with schizophrenia, including the striatum, hippocampus, and cortex (Hersch and Levey, 1995; Levey et al., 1991; Rouse et al., 1999), and can function as autoreceptors in the striatum and midbrain (Tzavara et al., 2004; Zhang et al., 2002), as well as postsynaptic modulatory receptors in the striatum, neocortex, and hippocampus (Levey et al., 1991; Zang and Creese, 1997). Since efficacy was observed after 10-day, once daily administration of 10 mg/kg VU0467154 on enhancing the acquisition of memory in the cue-mediated conditioned freezing task and reversing both MK-801-induced impairments in the acquisition of a context-mediated conditioned freezing paradigm and induction of hyperactivity, these findings are consistent with the interpretation that selective M4 PAMs appear to provide a sufficient therapeutic index for potentially improving some of the positive and cognitive symptoms observed schizophrenia within the same dose range.

    View all citing articles on Scopus
    View full text